Monthly intravitreal bevacizumab for macular edema after iodine-125 plaque radiotherapy of uveal melanoma.

Abstract

PURPOSE:

To examine the efficacy of monthly injections of intravitreal bevacizumab (IVB) for macular edema after iodine-125 plaque radiotherapy of uveal melanoma.

METHODS:

We studied 36 patients with macular edema after plaque radiotherapy of uveal melanoma in this noncomparative, interventional case series. All eyes were treated with 4 monthly injections of IVB. Central macular thickness (CMT) and best-corrected visual acuity (BCVA) were measured before each injection and 4-6 months after the first injection. The main outcome measures were change in CMT and BCVA.

RESULTS:

At 4-6 months following the first IVB, 20 eyes (56%) had decreased CMT, 11 eyes (31%) had stable CMT, and 5 eyes (14%) had increased CMT. The mean change in CMT and the mean percent change in CMT at 4-6 months compared to baseline were -91 µm (-20%) in all eyes, -174 µm (-37%) in the group with decreased macular thickness, -14 µm (-3%) in the group with stable macular thickness, and +69 µm (+17%) in the group with increased macular thickness. At 4-6 months, 15 eyes (42%) had increased BCVA, 16 eyes (44%) had stable BCVA, and 5 eyes (14%) had decreased BCVA. An increase in CMT was seen between the fourth monthly IVB injection and the final evaluation at 4-6 months after the first injection in all 3 groups of our study.

CONCLUSIONS:

At 4-6 months following the first injection, 4 monthly injections of IVB in eyes with macular edema after plaque radiotherapy of uveal melanoma decreased macular edema in 56% and improved BCVA in 42% of the treated eyes.

• Authors: Arman Mashayekhi, Duangnate Rojanaporn, Saad Al-Dahmash, Carol L Shields, Jerry A Shields
• Journal: European journal of ophthalmology (Eur J Ophthalmol) 2014 Mar-Apr Vol. 24 Issue 2 Pg. 228-34 ISSN: 1724-6016 [Electronic] United States
• PMID: 23934823 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Angiogenesis Inhibitors
• Antibodies, Monoclonal, Humanized
• Iodine Radioisotopes
• VEGFA protein, human
• Vascular Endothelial Growth Factor A
• Bevacizumab

Topics

• Adult
• Aged
• Aged, 80 and over
• Angiogenesis Inhibitors (therapeutic use)
• Antibodies, Monoclonal, Humanized (therapeutic use)
• Bevacizumab
• Brachytherapy (adverse effects)
• Female
• Humans
• Intravitreal Injections
• Iodine Radioisotopes (adverse effects)
• Macular Edema (drug therapy, etiology, physiopathology)
• Male
• Melanoma (radiotherapy)
• Middle Aged
• Radiation Injuries (drug therapy, etiology, physiopathology)
• Retina (physiopathology, radiation effects)
• Time Factors
• Tomography, Optical Coherence
• Treatment Outcome
• Uveal Neoplasms (radiotherapy)
• Vascular Endothelial Growth Factor A (antagonists & inhibitors)
• Visual Acuity